ELAM C. TOONE JR., M.D., F.A.C.P.; W. ROBERT IRBY, M.D.
In recent months much information has accumulated concerning the therapeutic effects and toxic potentialities of a new synthetic "antirheumatic" agent, phenylbutazone, commercially known as Butazolidin. This drug was first synthesized by H. Stenzl, of Basel, Switzerland, in 1946. It is a pyrazol whose chemical designation is sodium-4-butyl-1, 2 diphenyl-3,5-pyrazolidinedione⌖. Originally it was used in Europe as a solvent for aminopyrine in a preparation known as Irgapyrin, administered by intramuscular injection. In this country the phenylbutazone component has been used alone for the most part, and administered orally. A number of observers have found it to be quite helpful in the
TOONE EC, IRBY WR. EVALUATION OF PHENYLBUTAZONE (BUTAZOLIDIN) IN THE TREATMENT OF RHEUMATOID SPONDYLITIS: REPORT OF 50 CASES1. Ann Intern Med. ;41:70–78. doi: 10.7326/0003-4819-41-1-70
Download citation file:
Published: Ann Intern Med. 1954;41(1):70-78.
Infectious Disease, Rheumatology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use